Coronary hemodynamic effects of systemic thrombolysis in patients with unstable angina.
Intracoronary (i.c.) thrombus is a frequent finding in patients with unstable angina (UA). Accordingly, thrombolytic treatment could be beneficial, as resolution of thrombus might result in increased delivery of blood flow to the ischemic regions. To test this hypothesis, we studied 13 patients with active UA and ST-segment shift in the anterior leads. Coronary angiography was performed and great cardiac vein blood flow (GCVF; thermodilution) was measured in all patients 25 +/- 14 h after the last chest pain episode. Following angiography, patients received i.v. urokinase (UK: 1,000,000 IU/30 min); aortic pressure and GCVF were measured before and every 10 min following drug infusion, for a total time of 90 min. At baseline angiography, 5 of 13 patients (Group 1) had evidence of i.c. thrombus (intraluminal filling defect or thrombotic subocclusion) in the ischemia-related left coronary artery, whereas 8 patients (Group 2) did not. Group analysis showed that UK increased GCVF and decreased anterior coronary resistance in Group 1 (respectively, from 86 +/- 33 to 114 +/- 41 ml/min: p less than 0.005; and from 1.37 +/- 0.68 to 1.01 +/- 0.44 mmHg/ml/min: p less than 0.05) but not in Group 2 (both: p = NS). In conclusion, UK has been shown to increase regional coronary blood flow in selected patients presenting with active UA, as well as evidence of i.c. thrombus at early angiography. Heterogeneity of angiographic findings could explain controversies in trials dealing with thrombolysis in UA.
Pozzati
A
A
Institute of Patologia Medica and C.C.U., University of Bologna, Italy.
Bugiardini
R
R
Ottani
F
F
Morgagni
G L
GL
Puddu
P
P
D000368:Aged; D000789:Angina, Unstable / Q000150:complications / Q000503:physiopathology*; D003326:Coronary Circulation / Q000187:drug effects*; D003328:Coronary Thrombosis / Q000150:complications / Q000188:drug therapy; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology* / Q000627:therapeutic use
D014568:Urokinase-Type Plasminogen Activator